

Special Issue

Microalgae and Age-Related Diseases: New Innovative Approaches to Age-Old Problems

Message from the Guest Editors

Today, an increasing number of individuals are impacted by long-term chronic illnesses, such as cardiovascular and/or neurodegenerative disorders, diabetes, hypertension, liver disease, and chronic kidney disease, among others. Despite the advances in therapeutic approaches made in recent years, age-related ailments continue to pose a significant risk to human health. Therefore, it is crucial to create innovative treatment methods, including the development of new medications. A plethora of novel biomolecules derived from Microalgae have the potential to exhibit antioxidant, antibacterial, antitumor, regenerative, antihypertensive, neuroprotective, and immunostimulating effects, making them crucial to the biomedical and pharmaceutical industries. This Special Issue seeks to gather fresh and compelling high-quality manuscripts, such as research articles and comprehensive reviews, that focus on age-related diseases and the use of therapies utilizing biomolecules and extracts derived from microalgae. Studies involving human subjects or animal models are permissible.

Guest Editors

Dr. D. Craig Willcox


Dr. Richard C. Allsopp

Dr. Bradley Willcox

Dr. Giovanni Scapagnini

Deadline for manuscript submissions

closed (30 June 2024)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/192145

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))